GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Virios Therapeutics Inc (NAS:VIRI) » Definitions » ROC (Joel Greenblatt) %

Virios Therapeutics (Virios Therapeutics) ROC (Joel Greenblatt) % : -1,375.92% (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Virios Therapeutics ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Virios Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -1,375.92%.

The historical rank and industry rank for Virios Therapeutics's ROC (Joel Greenblatt) % or its related term are showing as below:

VIRI' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -6852.74   Med: -4008.57   Max: -1382.86
Current: -1382.86

During the past 6 years, Virios Therapeutics's highest ROC (Joel Greenblatt) % was -1382.86%. The lowest was -6852.74%. And the median was -4008.57%.

VIRI's ROC (Joel Greenblatt) % is ranked worse than
71.28% of 1466 companies
in the Biotechnology industry
Industry Median: -332.005 vs VIRI: -1382.86

Virios Therapeutics's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Virios Therapeutics ROC (Joel Greenblatt) % Historical Data

The historical data trend for Virios Therapeutics's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Virios Therapeutics ROC (Joel Greenblatt) % Chart

Virios Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial - -6,852.74 -4,895.46 -3,121.67 -1,387.77

Virios Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,332.19 -1,594.60 -4,996.08 -930.88 -1,375.92

Competitive Comparison of Virios Therapeutics's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, Virios Therapeutics's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Virios Therapeutics's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Virios Therapeutics's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Virios Therapeutics's ROC (Joel Greenblatt) % falls into.



Virios Therapeutics ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.848) - (0.359 + 0 + 0)
=0.489

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.845) - (0.57 + 0 + 0)
=0.275

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Virios Therapeutics for the quarter that ended in Mar. 2024 can be restated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-5.256/( ( (0 + max(0.489, 0)) + (0 + max(0.275, 0)) )/ 2 )
=-5.256/( ( 0.489 + 0.275 )/ 2 )
=-5.256/0.382
=-1,375.92 %

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Virios Therapeutics  (NAS:VIRI) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Virios Therapeutics ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Virios Therapeutics's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Virios Therapeutics (Virios Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
44 Milton Avenue, Alpharetta, GA, USA, 30009
Virios Therapeutics Inc is a development-stage biotechnology company. It is focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response such as fibromyalgia. The company is engaged in the development of its product, IMC-1, for people who are suffering from fibromyalgia.
Executives
William Pridgen director 44 MILTON AVENUE, ALPHARETTA GA 30009
Gregory Scott Duncan director, officer: Chief Executive Officer 44 MILTON AVENUE, ALPHARETTA GA 30009
Richard James Whitley director UAB, CHB 303, 1600 7TH AVENUE SOUTH, BIRMINGHAM AL 35233-1711
Angela Walsh officer: VP of Finance 44 MILTON AVENUE, ALPHARETTA GA 30009
De La Rosa Abel director 44 MILTON AVENUE, ALPHARETTA GA 30009
John C Thomas director 8601 SIX FORKS ROAD, SUITE 160, RALEIGH NC 27615
David R Keefer director 44 MILTON AVENUE, ALPHARETTA GA 30009
Ralph Grosswald officer: Vice President of Operations 44 MILTON AVENUE, ALPHARETTA GA 30009
Roger Michael Gendreau officer: Chief Medical Officer 44 MILTON AVENUE, ALPHARETTA GA 30009
Richard Alan Burch director 44 MILTON AVENUE, ALPHARETTA GA 30009

Virios Therapeutics (Virios Therapeutics) Headlines

From GuruFocus

Virios Therapeutics Announces First Quarter 2023 Financial Results

By sperokesalga sperokesalga 05-11-2023